Status:
COMPLETED
INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors
Lead Sponsor:
University Hospital, Lille
Conditions:
Pancreas Cancer
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The study is particularly innovative as it will accurately analyze the microscopic characteristics of the stroma, tumor budding and mucin expression in adenocarcinomas of the pancreas, using a compara...
Eligibility Criteria
Inclusion
- Patients \> 18 years of age at diagnosis
- Primary pancreatic cancer patients operated on in one of the 4 centres between 2001 and 2016
- Histopathological diagnosis of excreto-pancreatic adenocarcinoma of the pancreas, ductal adenocarcinoma or classical adenocarcinoma
- Tissue blocks (FFPE) available (tumour/healthy tissue)
- Affiliated to a social security scheme
Exclusion
- Absence of Primary Cancer Tissue Blocks (PCTBs)
- Paraffin block fixed in Bouin or AFA
- Patient Refusal
- Pancreatic cancer not corresponding to a conventional excretopancreatic adenocarcinoma such as: carcinoma on intraductal papillary mucinous neoplasm, endocrine tumor/carcinoma, acinar cell carcinoma, ...).
- Patient died due to post-surgical complications (death within 30 days post-surgery).
- Surgical resection of macroscopic R2 type.
Key Trial Info
Start Date :
February 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 22 2025
Estimated Enrollment :
342 Patients enrolled
Trial Details
Trial ID
NCT04436679
Start Date
February 2 2021
End Date
February 22 2025
Last Update
March 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hop Claude Huriez Chu Lille
Lille, France, 59037